ArticleACS omega2026
Predicting Oncogenic Mutants of Epidermal Growth Factor Receptor in Lung Cancer by Molecular Dynamics Simulation with Machine Learning.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The epidermal growth factor receptor (EGFR) is a frequently mutated protein kinase found in patients suffering from non-small cell lung cancer (NSCLC). Although therapeutic drugs targeting EGFR are available, not all patients respond to these drugs, and it is not yet known whether some clinically detected mutations are actionable. Although the oncogenicity of some mutants is well established, many mutants found in patients are not yet classified or classified as Variants of Uncertain Significance. For newly discovered rare mutants, strong evidence supporting their classification into oncogenic or benign is often lacking. Under such situations, multiple pieces of evidence can still help classification, even if each individual piece of evidence is weaker. Computational predictions have been considered as supporting information by the Standard Operating Procedure (SOP) of the Clinical Genome Resource/Cancer Genomics Consortium/Variant Interpretation for Cancer Consortium (ClinGen/CGC/VICC). The SOP considers predictions from multiple computational programs as providing only one piece of supporting information to avoid double counting because these programs share common approaches. A computational approach that explicitly accounts for the conformational effects of mutations via molecular dynamics (MD) simulation could add another piece of complementary supporting information. We tested the hypothesis that features of structural dynamics observed from MD simulation could help distinguish oncogenic from benign mutants. To this end, we performed three independent MD simulations lasting 1 μs each for wild-type EGFR and 32 of its oncogenic or benign mutants. We found that random forest machine-learning models constructed using suitable structural features were able to distinguish oncogenic and benign mutations effectively. Although we did not supply features of structural motifs commonly used by scientists to distinguish active and inactive conformations, our machine-learning approach identified and utilized some features associated with these motifs for classifying EGFR mutants.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.